Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / BioXcel Therapeutics, Inc.

M&Asold assets or a business (SEC 8-K)30 Oct 2026

BioXcel Therapeutics, Inc.

30 Oct 2026: Sold assets or a business (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
30 Oct 2026
Ticker
BTAIQ
Role
Sold assets or a business
Sector
Pharma and biotech
Sic
2834
Items
2.01, 5.02, 5.03, 9.01
Summary
As previously disclosed, on August 27, 2026, BioXcel Therapeutics, Inc. (the " Company ") and its subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (together with the Company, the " Debtors ") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code (the "
Location
New Haven, CT
State
Connecticut
Country
United States
SEC CIK
1720893
Reference
0001104659-26-120737
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at BioXcel Therapeutics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Sold assets or a business

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.